Zydus Lifesciences launches Anyra, India’s first homegrown Aflibercept 2 mg biosimilar, offering affordable treatment for AMD, DR, DME, RVO, and mCNV, boosting access to advanced retinal care nationwide.
Novartis reported positive Phase III RemIND trial results for remibrutinib in chronic inducible urticaria, showing higher complete response rates than placebo and moving closer to the first targeted therapy for CIndU.
GSK plc has reported strong real-world results for its RSV vaccine, showing major reductions in RSV-related hospitalizations and serious complications in adults aged 60 and older at RSVVW’26 in Rome.
Dr Reddy’s Laboratories has acquired the India trademarks of two hormone replacement therapy drugs from Mercury Pharma for $32.15 million, strengthening its women’s health portfolio and marking its entry into the growing HRT segment.
Eli Lilly is establishing India as a strategic center point in its global supply chain, with the assistance of the robust contract manufacturing ecosystem
.png "Roche Advances PMN Treatment With Phase III Success")
Roche has announced a major breakthrough in primary membranous nephropathy after its Phase III MAJESTY trial showed higher complete remission rates with Gazyva/Gazyvaro compared to tacrolimus, marking a potential shift in rare kidney disease care.
Rx Propellant is scaling up in Genome Valley with a USD 100 million investment in a new life sciences campus. The move strengthens Hyderabad’s global biotech standing and meets rising demand for advanced lab space.
Teva and Sanofi reveal duvakitug’s 44-week success, showing lasting remission in ulcerative colitis and Crohn’s patients, reinforcing TL1A as a promising treatment target.
Aster Volunteers launches two new Mobile Medical Units in Tirupati and Anekal, expanding healthcare access in underserved communities across India.
Eli Lilly’s Retevmo delivers significant gains in event-free survival for early-stage RET fusion-positive NSCLC, marking a breakthrough in targeted lung cancer therapy.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")